Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study

Roberta Gagliardini; Barbara Rossetti; Claudia Bianco; S Rusconi; Manuela Colafigli; R Prinapori; D Francisci; A Fantauzzi; G Orofino; F Vignale; Simona Di Giambenedetto; Andrea De Luca

doi:10.7448/IAS.17.4.19818

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study

Roberta Gagliardini, Barbara Rossetti, Claudia Bianco, S Rusconi, Manuela Colafigli, R Prinapori, D Francisci, A Fantauzzi, G Orofino, F Vignale, Simona Di Giambenedetto, Andrea De Luca

Risultato della ricerca: Contributo in rivista › Contributo a convegno › peer review

Abstract

HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.

Lingua originale	English
pagine (da-a)	19818-19818
Numero di pagine	1
Rivista	Journal of the International AIDS Society
Volume	17
DOI	https://doi.org/10.7448/IAS.17.4.19818
Stato di pubblicazione	Pubblicato - 2014
Evento	HIV Drug Therapy Glasgow Congress 2014 - Glasgow Durata: 2 nov 2014 → 6 nov 2014

Keywords

HCV
HIV
Risk factor
liver
therapy

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.7448/IAS.17.4.19818

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Gagliardini, R., Rossetti, B., Bianco, C., Rusconi, S., Colafigli, M., Prinapori, R., Francisci, D., Fantauzzi, A., Orofino, G., Vignale, F., Di Giambenedetto, S., & De Luca, A. (2014). Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study. Journal of the International AIDS Society, 17, 19818-19818. https://doi.org/10.7448/IAS.17.4.19818

@article{97296dd9ed9f487a82b049fcade4a3e6,

title = "Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study",

abstract = "HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.",

keywords = "HCV, HIV, Risk factor, liver, therapy, HCV, HIV, Risk factor, liver, therapy",

author = "Roberta Gagliardini and Barbara Rossetti and Claudia Bianco and S Rusconi and Manuela Colafigli and R Prinapori and D Francisci and A Fantauzzi and G Orofino and F Vignale and {Di Giambenedetto}, Simona and {De Luca}, Andrea",

year = "2014",

doi = "10.7448/IAS.17.4.19818",

language = "English",

volume = "17",

pages = "19818--19818",

journal = "Journal of the International AIDS Society",

issn = "1758-2652",

publisher = "London: BioMed Central",

note = "HIV Drug Therapy Glasgow Congress 2014 ; Conference date: 02-11-2014 Through 06-11-2014",

}

Gagliardini, R, Rossetti, B, Bianco, C, Rusconi, S, Colafigli, M, Prinapori, R, Francisci, D, Fantauzzi, A, Orofino, G, Vignale, F, Di Giambenedetto, S & De Luca, A 2014, 'Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study', Journal of the International AIDS Society, vol. 17, pagg. 19818-19818. https://doi.org/10.7448/IAS.17.4.19818

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study. / Gagliardini, Roberta; Rossetti, Barbara; Bianco, Claudia et al.
In: Journal of the International AIDS Society, Vol. 17, 2014, pag. 19818-19818.

Risultato della ricerca: Contributo in rivista › Contributo a convegno › peer review

TY - JOUR

T1 - Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study

AU - Gagliardini, Roberta

AU - Rossetti, Barbara

AU - Bianco, Claudia

AU - Rusconi, S

AU - Colafigli, Manuela

AU - Prinapori, R

AU - Francisci, D

AU - Fantauzzi, A

AU - Orofino, G

AU - Vignale, F

AU - Di Giambenedetto, Simona

AU - De Luca, Andrea

PY - 2014

Y1 - 2014

N2 - HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.

AB - HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.

KW - HCV

KW - HIV

KW - Risk factor

KW - liver

KW - therapy

KW - HCV

KW - HIV

KW - Risk factor

KW - liver

KW - therapy

UR - http://hdl.handle.net/10807/61288

U2 - 10.7448/IAS.17.4.19818

DO - 10.7448/IAS.17.4.19818

M3 - Conference article

SN - 1758-2652

VL - 17

SP - 19818

EP - 19818

JO - Journal of the International AIDS Society

JF - Journal of the International AIDS Society

T2 - HIV Drug Therapy Glasgow Congress 2014

Y2 - 2 November 2014 through 6 November 2014

ER -

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo